Edition:
United Kingdom

Zealand Pharma A/S (ZELA.CO)

ZELA.CO on Copenhagen Stock Exchange

93.00DKK
21 Feb 2018
Change (% chg)

kr.1.40 (+1.53%)
Prev Close
kr.91.60
Open
kr.91.40
Day's High
kr.93.00
Day's Low
kr.91.00
Volume
64,753
Avg. Vol
129,911
52-wk High
kr.141.00
52-wk Low
kr.78.50

Chart for

About

Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and... (more)

Overall

Beta: 0.84
Market Cap(Mil.): kr.3,751.36
Shares Outstanding(Mil.): 30.75
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Zealand Pharma And Uniquest Collaborate To Develop Novel Drug Candidates

* REG-ZEALAND PHARMA AND UNIQUEST COLLABORATE TO DEVELOP NOVEL DRUG CANDIDATES FOR GASTROINTESTINAL DISEASES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

20 Feb 2018

BRIEF-Zealand Reports Royalty Revenue Of DKK 11.3 Mln For Q4 2017

* REG-ZEALAND REPORTS ROYALTY REVENUE FOR THE FOURTH QUARTER OF 2017

07 Feb 2018

Biotech Zealand Pharma bets on self-marketing over big pharma partnerships

GLOSTRUP, Denmark, Jan 30 Denmark's Zealand Pharma is pinning its strategy on rare disease drugs that the small biotech can market itself after seeing disappointing income from a diabetes drug marketed by partner Sanofi, its chief executive said.

30 Jan 2018

BRIEF-Zealand: Clinical Evidence Support Potential For Glepaglutide

* ZEALAND HAS COMPLETED A PHARMACOKINETIC (PK) STUDY WITH GLEPAGLUTIDE THAT CONFIRMS POTENTIAL FOR ONCE-WEEKLY DOSING

23 Jan 2018

BRIEF-Zealand Pharma Announces Progress To Phase 3 With Dasiglucagon For The Treatment Of Congenital Hyperinsulinism

* ZEALAND PHARMA ANNOUNCES PROGRESS TO PHASE 3 WITH DASIGLUCAGON FOR THE TREATMENT OF CONGENITAL HYPERINSULINISM IN FIRST HALF 2018

19 Jan 2018

BRIEF-Zealand Pharma Makes Initial USD 1.5 Mln Equity Investment In Beta Bionics

* ZEALAND PHARMA MAKES AN INITIAL USD 1.5 MILLION EQUITY INVESTMENT IN SERIES B OFFERING OF BETA BIONICS, INC.

21 Dec 2017

BRIEF-Zealand Pharma Initiates Phase 3 Trial With Dasiglucagon

* ZEALAND PHARMA INITIATES THE PIVOTAL PHASE 3 TRIAL WITH DASIGLUCAGON FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA IN DIABETES

07 Dec 2017

BRIEF-Zealand Pharma Q3 operating loss at DKK 38.2 mln ​

* ‍MAINTAINS ITS REVENUE GUIDANCE OF A CONTINUED INCREASE IN ROYALTY PAYMENTS FROM SANOFI.​

08 Nov 2017

BRIEF-Zealand reports royalty revenue Of DKK 10.3 mln for Q3

* REG- ZEALAND REPORTS ROYALTY REVENUE FOR THE THIRD QUARTER OF 2017

02 Nov 2017

BRIEF-Zealand Pharma granted orphan drug designation by FDA

* REG-U.S. FDA GRANTS ORPHAN DRUG DESIGNATION TO GLEPAGLUTIDE FOR THE TREATMENT OF SHORT BOWEL SYNDROME

24 Oct 2017

Earnings vs. Estimates